Lead Product(s) : Delandistrogene Moxeparvovec,Imlifidase
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Sarepta Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SRP-9001 (delandistrogene moxeparvovec), is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.
Product Name : SRP-9001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 11, 2022
Lead Product(s) : Delandistrogene Moxeparvovec,Imlifidase
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Sarepta Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imlifidase
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Sarepta Therapeutics
Deal Size : $407.5 million
Deal Type : Licensing Agreement
Details : Hansa Biopharma Granted Sarepta an exclusive, worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy treatment in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD).
Product Name : Idefirix
Product Type : Enzyme
Upfront Cash : $10.0 million
February 07, 2020
Lead Product(s) : Imlifidase
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Sarepta Therapeutics
Deal Size : $407.5 million
Deal Type : Licensing Agreement